Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 26 of the 33 sources its claims cite were checked for support.

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Open access

Abstract

Background and Aims: Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. This investigation sought to determine whether low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), and triglycerides are sufficient for routine cardiovascular care. Methods: A sample of 293 876 UK Biobank adults (age: 40–73 years, 42% men), free of cardiovascular disease, with a median follow-up for new-onset ASCVD of 11 years was included. Distribution of apoB at pre-specified levels of LDL-C, non-HDL-C, and triglycerides was examined graphically, and 10-year ASCVD event rates were compared for high vs. low apoB. Residuals of apoB were constructed after regressing apoB on LDL-C, non-HDL-C, and log-transformed triglycerides and used as predictors in a proportional hazards regression model for new-onset ASCVD adjusted for standard risk factors, including HDL-C. Results: ApoB was highly correlated with LDL-C and non-HDL-C (Pearson’s r = .96, P < .001 for both) but less so with log triglycerides (r = .42, P < .001). However, apoB ranges necessary to capture 95% of all observations at pre-specified levels of LDL-C, non-HDL-C, or triglycerides were wide, spanning 85.8–108.8 md/dL when LDL-C 130 mg/dL, 88.3–112.4 mg/dL when non-HDL-C 160 mg/dL, and 67.8–147.4 md/dL when triglycerides 115 mg/dL. At these levels (±10 mg/dL), 10-year ASCVD rates for apoB above mean + 1 SD vs. below mean − 1 SD were 7.3 vs. 4.0 for LDL-C, 6.4 vs. 4.6 for non-HDL-C, and 7.0 vs. 4.6 for triglycerides (all P < .001). With 19 982 new-onset ASCVD events on follow-up, in the adjusted model, residual apoB remained statistically significant after accounting for LDL-C and HDL-C (hazard ratio 1.06, 95% confidence interval 1.0–1.07), after accounting for non-HDL-C and HDL-C (hazard ratio 1.04, 95% confidence interval 1.03–1.06), and after accounting for triglycerides and HDL-C (hazard ratio 1.13, 95% confidence interval 1.12–1.15). None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model. Conclusions: High variability of apoB at individual levels of LDL-C, non-HDL-C, and triglycerides coupled with meaningful differences in 10-year ASCVD rates and significant residual information contained in apoB for prediction of new-onset ASCVD events demonstrate that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care.

Overview

CoChat Summary

TL;DR

In UK Biobank adults free of cardiovascular disease, apoB varied widely at given levels of LDL-C, non-HDL-C, and triglycerides and retained significant ASCVD risk information after adjustment for those markers. The authors conclude that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care.

Key findings

  • Among 293,876 UK Biobank adults with median follow-up of 10.95 years and 19,982 ASCVD events, apoB was highly correlated with LDL-C and non-HDL-C (Pearson’s r = .96, P < .001 for both) but less so with log triglycerides (r = .42, P < .001).
  • Despite high correlation, apoB ranges capturing ~95% of observations at fixed lipid levels were wide: 85.8–108.8 mg/dL when LDL-C was 130 mg/dL, 88.3–112.4 mg/dL when non-HDL-C was 160 mg/dL, and 67.8–147.4 mg/dL when triglycerides were 115 mg/dL.
  • At those levels ±10 mg/dL, 10-year ASCVD rates for apoB above mean + 1 SD vs below mean − 1 SD were 7.3 vs 4.0 for LDL-C 130 mg/dL, 6.4 vs 4.6 for non-HDL-C 160 mg/dL, and 7.0 vs 4.6 for triglycerides 115 mg/dL (all P < .001).
  • In adjusted Cox models, residual apoB remained significant after accounting for LDL-C and HDL-C (HR 1.06, 95% CI 1.04–1.07), after non-HDL-C and HDL-C (HR 1.04, 95% CI 1.03–1.06), and after triglycerides and HDL-C (HR 1.13, 95% CI 1.12–1.15); residuals of LDL-C, non-HDL-C, or log triglycerides were not significant when apoB was included.

Methods

  • Prospective cohort analysis using 293,876 UK Biobank adults aged 40–73 years, 42% men, free of cardiovascular disease and not receiving lipid-lowering therapy at baseline, with median follow-up for new-onset ASCVD of 11 years.
  • ApoB distributions were examined graphically at pre-specified LDL-C, non-HDL-C, and triglyceride levels; 10-year ASCVD event rates were compared for high vs low apoB.
  • Residuals of apoB were constructed after regressing apoB on LDL-C, non-HDL-C, and log-transformed triglycerides and used as predictors in proportional hazards regression models for new-onset ASCVD adjusted for standard risk factors, including HDL-C.

Limitations

  • Stated in the paper: the analysis is limited to one European country with racial and ethnic subgroups representing that country, and the focus is on identifying the most accurate lipid marker rather than constructing the best risk prediction algorithms.
  • Stated in the paper: a trial comparing care guided by different lipid parameters is neither likely nor feasible, so the evidence comes from an observational cohort study.
  • Evident in the text: the Methods report a final analytic sample of 293,883 adults, whereas the abstract, results, and Table 1 report 293,876 participants.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehae258

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Structured Graphical Abstract Illustration of residual discordance and variance analysis of apoB and LDL-C/non-HDL-C in UK Biobank. LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol; apoB, apolipoprotein B.
Structured Graphical Abstract Illustration of residual discordance and variance analysis of apoB and LDL-C/non-HDL-C in UK Biobank. LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non–high-density lipoprotein cholesterol; apoB, apolipoprotein B.CC BY-NC · PubMed Central
Figure 1 Distribution of apoB at different levels of low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol. The figure depicts density plots of apoB levels at pre-selected levels of low-density lipoprotein cholesterol (A) and non–high-density lipoprotein cholesterol (B). For each value of low-density lipoprotein cholesterol (A) or non–high-density lipoprotein cholesterol (B), the figure displays a histogram of apoB values for all individuals with that value of low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol ±1. We note the location of the histograms shifting from left to right as the values of low-density lipoprotein cholesterol (A) or non–high-density lipoprotein cholesterol (B) increase. At the same time, the range covered by the histograms remains wide
Figure 1 Distribution of apoB at different levels of low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol. The figure depicts density plots of apoB levels at pre-selected levels of low-density lipoprotein cholesterol (A) and non–high-density lipoprotein cholesterol (B). For each value of low-density lipoprotein cholesterol (A) or non–high-density lipoprotein cholesterol (B), the figure displays a histogram of apoB values for all individuals with that value of low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol ±1. We note the location of the histograms shifting from left to right as the values of low-density lipoprotein cholesterol (A) or non–high-density lipoprotein cholesterol (B) increase. At the same time, the range covered by the histograms remains wideCC BY-NC · PubMed Central
Figure 2 Ten-year risk of atherosclerotic cardiovascular disease for high vs. low apoB at different levels of low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol. The figure depicts 10-year Kaplan–Meier rates of atherosclerotic cardiovascular disease for high (at least 1 SD above the mean; right bar) vs. low (at least 1 SD below the mean; left bar) apoB levels at pre-selected levels of low-density lipoprotein cholesterol ±10 mg/dL (A) and non–high-density lipoprotein cholesterol ±10 mg/dL (B)
Figure 2 Ten-year risk of atherosclerotic cardiovascular disease for high vs. low apoB at different levels of low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol. The figure depicts 10-year Kaplan–Meier rates of atherosclerotic cardiovascular disease for high (at least 1 SD above the mean; right bar) vs. low (at least 1 SD below the mean; left bar) apoB levels at pre-selected levels of low-density lipoprotein cholesterol ±10 mg/dL (A) and non–high-density lipoprotein cholesterol ±10 mg/dL (B)CC BY-NC · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 3 Not checked · 49 Own results and interpretations

44 more claims · 1 with their cited sources checked

Create a free account to see all 60 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 7
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 34 references

Cited by

See all 139

Metadata

Authors
Sniderman, A. D., Dufresne, L., Pencina, K. M., Bilgic, S., Thanassoulis, G., & Pencina, M. J.
Affiliations
  • McGill University Health Centre (CA)
  • Brigham and Women's Hospital (US)
  • Duke University (US)
Corresponding author
Sniderman, Allan D
Venue
European Heart Journal
Published
2024-05-03
Volume
45
Issue
27
Pages
2410-2418
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4396624888
Cited by
139
References
34
Citations by year
2026: 74 · 2025: 51 · 2024: 14
FWCI
39.07
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Doggone Foundation
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
apolipoprotein B, non-HDL cholesterol, LDL cholesterol, triglycerides, atherosclerotic cardiovascular disease, cardiovascular risk prediction, residual cardiovascular risk, cardiovascular disease prevention, lipid biomarkers, cardiovascular risk stratification
MeSH terms
Adult, Aged, Apolipoproteins B, Cardiovascular Diseases, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. https://app.cochat.ai/papers/10.1093/eurheartj/ehae258
The paper
Sniderman, A. D., Dufresne, L., Pencina, K. M., Bilgic, S., Thanassoulis, G., & Pencina, M. J. (2024). Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal. https://doi.org/10.1093/eurheartj/ehae258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.